Valproic acid is a Small Molecule owned by AbbVie, and is involved in 1 clinical trial, which is ongoing.

Valproic acid binds to and inhibits gamma-aminobutyric acid (GABA) transaminase and its anticonvulsant activity may be exerted by increasing brain concentration of GABA and by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. It may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels.

The revenue for Valproic acid is expected to reach a total of $173m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Valproic acid NPV Report.

Valproic acid is currently owned by AbbVie. Kyowa Kirin is the other company associated in development or marketing of Valproic acid.

Valproic acid Overview

Valproic acid (Depakene, Depakene R, Vodsso) is an anti convulsant and antimanic agent. It is formulated as soft gelatin capsules, coated tablets, granules and syrup for oral route of administration. Depakene is used as a monotherapy for complex partial seizures, adjunctive therapy for simple, complex and multiple seizure types that include absence seizures, in the prophylaxis of migraine headaches, mania and manic depression and various epilepsy (small seizures, focal seizures, psychomotor seizures and mixed seizures).

Kyowa Kirin Overview

Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY352,246 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 17%, compared to an operating margin of 15.9% in FY2020. In FY2021, the company recorded a net margin of 14.9%, compared to a net margin of 14.8% in FY2020. The company reported revenues of JPY98,504 million for the third quarter ended September 2022, an increase of 1% over the previous quarter.

Quick View – Valproic acid

Report Segments
  • Innovator (NME)
Drug Name
  • Valproic acid
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.